The ROW license for Laninamivir will be the result of current management, I'll wait till then to give my opinion. Up till now I have to say that I'm pretty happy with their performance.
I'm very happy holding to see the upcoming license deals because I have faith the management (along with DS) can pull off a fantastic deal. I know they have tried to license the compound earlier but I admire there willingness to refuse low ball deals... Biota know what they have and are willing to hold out to get the best value for shareholders.
Of course, I'll be happier (and willing to vote in favour of remuneration reports) if they listed on the NASDAQ :)
Not sure how I'll vote at the AGM... I don't like incentives which are already in the money by a large margin, what's the point just give it as salary instead?
BTA Price at posting:
$2.78 Sentiment: Buy Disclosure: Held
